ArticleHuman vaccines & immunotherapeutics2026
Post-vaccination HPV prevalence, genotype distribution, and associated factors among vaccinated women in China: A cross-sectional study.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate human papillomavirus (HPV) prevalence and genotype distribution among vaccinated women and to identify the factors associated with post-vaccination HPV infection. Women who received HPV vaccine and had the thin-layer liquid-based cytology test (TCT) and HPV genotype testing before HPV vaccination were recruited. Each participant was required to complete an online questionnaire, and cervical specimen was collected for TCT and HPV genotype testing. The epidemiology of HPV infection and genotype was described. The factors associated with HPV infection post-vaccination were identified through multivariate analysis, presenting the adjusted odds ratio (AOR) with its 95% confidence interval (95%CI). A total of 893 eligible women participated. The prevalence of HPV post-vaccination was 8.51%. The common high-risk HPV (hr-HPV) were HPV52, HPV59, HPV58 and the common low-risk HPV (lr-HPV) was HPV53. Factors associated with HPV infection post-vaccination included aged ≥40y (AOR = 2.92), married status (AOR = 1.56), receiving the first dose of HPV vaccine after sexual debut (OR = 2.57), lr-HPV positive pre-vaccination (AOR = 2.35) and hr-HPV positive pre-vaccination (AOR = 5.72). The prevalence of HPV post-vaccination was lower than that of pre-vaccination and the common genotypes changed to those not covered by HPV vaccine administrated. Age, marital status, timing of HPV vaccination and prior HPV infection before HPV vaccination were identified as the factors associated with HPV infection post-vaccination. Receiving HPV vaccination before sexual debut and ongoing HPV screening after vaccination were recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.